Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velusetrag in diabetic or idiopathic gastroparesis
NCT02267525Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of velusetrag in gastroparesis (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Gastroparesis Cardinal Symptoms Index 24-hour composite score at 4 weeks. Started Dec 2014; status: completed.
02
Drugs
velusetrag
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT02267525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267525.